Avacta's AVA6103 Cancer Drug Shows Superior Profile vs Enhertu in AACR 2026 Data

Key Takeaways

• AVA6103 demonstrated robust anticancer activity in patient-derived xenograft models with low FAP expression levels
• The drug candidate showed more favorable pharmacokinetic profile compared to the marketed ADC Enhertu
• Avacta’s pre|CISION platform displayed dual payload capability with first-ever in vivo efficacy data

---

Avacta Presents Breakthrough AVA6103 Data at AACR 2026

Avacta Group plc announced compelling new data for its lead cancer drug candidate AVA6103 at the American Association for Cancer Research (AACR) Annual Meeting 2026, demonstrating significant advantages over existing antibody-drug conjugates including the marketed therapy Enhertu®.

Superior Performance in Challenging Tumor Models

The FAP-Exd study revealed that AVA6103 maintained robust anticancer activity even in patient-derived xenograft (PDX) models with low fibroblast activation protein (FAP) expression. This finding is particularly significant as many current targeted therapies struggle with efficacy in tumors with low target expression levels.

The data showed AVA6103’s superior pharmacokinetic profile compared to Enhertu, suggesting potentially improved safety and dosing flexibility for patients. This advantage could translate to better tolerability and treatment outcomes in clinical settings.

Platform Technology Advances

Avacta’s proprietary pre|CISION® delivery platform demonstrated its dual payload capability for the first time in vivo, marking a significant technological milestone. This innovation could enable combination therapies within a single drug construct, potentially improving treatment efficacy while reducing side effects.

The dual payload approach represents a novel strategy in oncology drug development, allowing simultaneous delivery of multiple therapeutic agents to tumor sites with enhanced precision.

Market Implications and Development Timeline

These positive results strengthen AVA6103’s competitive position in the crowded antibody-drug conjugate market, which is projected to reach $15 billion by 2028. The favorable comparison to Enhertu, a commercially successful ADC, validates Avacta’s technological approach and could attract partnership interest from major pharmaceutical companies.

The company continues advancing AVA6103 through clinical development, with these AACR findings supporting potential regulatory discussions and future trial designs. The robust activity in low FAP expression models expands the potential patient population who could benefit from this treatment approach.

---

Frequently Asked Questions

What does this mean for cancer patients?

AVA6103 could offer a new treatment option with potentially better tolerability and effectiveness, especially for patients whose tumors have low levels of the target protein FAP.

When will AVA6103 be available to patients?

AVA6103 is still in clinical development. The timeline for potential approval depends on successful completion of ongoing and future clinical trials, which typically take several years.

How does AVA6103 compare to existing cancer treatments?

The data suggests AVA6103 has a more favorable safety profile than Enhertu and works effectively even in tumors with low target expression, potentially expanding treatment options for more patients.